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Toronto and London, Ontario, Canada
Objectives The objectives of this study were to examine: 1) B-type natriuretic peptide (BNP) response to pregnancy in women
with heart disease; and 2) the relationship between BNP levels and adverse maternal cardiac events during pregnancy.
Background Pregnancy imposes a hemodynamic stress on the heart. BNP might be a useful biomarker to assess the ability
of the heart to adapt to the hemodynamic load of pregnancy.
Methods This was a prospective study of women with structural heart disease seen at our center. Serial clinical data and
plasma BNP measurements were obtained during the first trimester, third trimester, and after delivery (6 weeks).
Results Seventy-eight pregnant women were studied; 66 women with heart disease (age 31  5 years), and 12 healthy
women (age 33  5 years). During pregnancy, the median peak BNP level was higher in women with heart dis-
ease compared with control subjects (median 79, interquartile range 51 to 152 pg/ml vs. median 35, interquar-
tile range 21 to 43 pg/ml, p  0.001). In women with heart disease, those with subaortic ventricular dysfunc-
tion had higher BNP levels (p  0.03). A BNP 100 pg/ml was measured in all women with events during
pregnancy (n  8). Sixteen women had increased BNP levels during pregnancy but did not have clinical events.
None of the women with BNP 100 pg/ml had events. BNP 100 pg/ml had a negative predictive value of
100% for identifying events during pregnancy.
Conclusions Many pregnant women with heart disease have increased BNP levels during pregnancy. Incorporating serial BNP
levels in into clinical practice can be helpful, specifically in adjudicating suspected adverse cardiac events during
pregnancy. (J Am Coll Cardiol 2010;56:1247–53) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.076e
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hregnancy is characterized by a number of adaptive hemo-
ynamic changes, including increases in plasma volume,
eart rate, and cardiac output. The increased volume load-
ng is thought to be a central mechanism underlying the
athogenesis of adverse maternal cardiac events during
regnancy. In the nonpregnant state, B-type natriuretic
eptide (BNP) increases in response to these types of
olume loading conditions and predicts the risk of adverse
utcomes in a variety of cardiac conditions (1–6). Although
linical and echocardiographic predictors of adverse cardiac
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010, accepted February 25, 2010.vents during pregnancy have been identified (7,8), risk
tratification is incomplete, and current risk stratification
oes not include evaluation of the adequacy of maternal
ardiac adaptation during pregnancy. Furthermore, because
he signs and symptoms of pregnancy can mimic those of
ardiac decompensation, clinical recognition of heart disease is
ore difficult during pregnancy and, therefore, there might be
role for additional markers such as serum BNP levels to
etect decompensation. The objectives of this study were: 1) to
rospectively study BNP levels in pregnant women with
tructural heart diseases compared with those without heart
isease; and 2) to determine the relationship between BNP
evels and adverse cardiac events during pregnancy.
ethods
tudy design. The study prospectively enrolled pregnant
omen with heart disease and healthy pregnant women
control subjects) receiving obstetric and cardiac care at our
enter. All women with structural congenital or acquired
eart disease followed during pregnancy in our clinic be-
ween November 2006 and June 2008 were asked to
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BNP and Pregnancy October 5, 2010:1247–53participate in the study. Women
with cardiac arrhythmias and
structurally normal hearts were
excluded. Women who pre-
sented late in pregnancy or at the
time of labor and delivery were
not included. Three women with
heart disease declined participa-
tion. All women were followed
throughout pregnancy and until
6 months after delivery in our
clinic. The study received ap-
roval from the institutional ethics review board, and all
articipating subjects gave written informed consent.
aseline and serial assessments. Clinical assessments and
enous blood samples were obtained at the time of clinical
isits. Baseline data were recorded at the time of the first
ntenatal visit (mean weeks gestation at the time of enroll-
ent: 14  5; 5 women were included that were first seen
fter the first trimester) and included: age; gestational age;
ravity and parity status; details pertaining to cardiac lesions
nd comorbid conditions such as hypertension, renal dis-
ase, or other conditions that might affect natriuretic pep-
ide levels; prior surgery/interventions; prior cardiac events;
se of cigarettes; and presence of cyanosis (oxygen satura-
ion 90%). When possible, the following serial measures
ere obtained in the first and third trimester and after
elivery (6 weeks after delivery): details pertaining to
linical status and adverse events, New York Heart Associ-
tion (NYHA) functional class, medication use, 12-lead
lectrocardiograms, and BNP plasma levels.
Baseline echocardiographic measures were obtained at
he time of the initial clinic visit. Left ventricular (LV)
olumes at end diastole and end systole were measured by
impson’s biplane method according to American Society
f Echocardiography guidelines, and ejection fraction was
alculated (9). Left ventricular dilation was defined as a LV
nd-diastolic volume 104 ml (9). Systemic (subaortic)
entricular dysfunction was defined as a left ventricular
jection fraction (LVEF) 55% (9). In patients with
ransposition complexes, the presence of subaortic right ven-
ricular dysfunction and dilation was determined qualitatively
y an experienced echocardiographer blinded to the natriuretic
eptide level. Subpulmonary ventricular size and function were
ssessed visually by an experienced echocardiographer and
raded as normal, mild, moderate, or severe dilation or hypo-
inesis, respectively. Left atrial volume was determined by the
rea-length method (9). Quantitation of inflow or outflow
bstruction, quantitation of valvular regurgitation, and esti-
ates of systolic pulmonary artery pressure were performed by
tandard methods (10). Pulmonary artery hypertension was
efined as a right ventricular systolic pressure 40 mm Hg in
he absence of right ventricular outflow tract obstruction.
isk assessment of adverse maternal cardiac events during
regnancy. A validated maternal cardiac risk score (Cardiac
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
IQR  interquartile range
LV  left ventricular
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Associationisease in Pregnancy risk score) (7) was calculated for each noman by assigning 1 point to each of the following
ariables: cardiac events before pregnancy (arrhythmia, heart
ailure, or stroke/transient ischemic attack), baseline NYHA
unctional classII or cyanosis (saturation90%), systemic
entricular dysfunction, and left heart obstruction. Systemic
entricular systolic dysfunction was defined as an ejection
raction 40%. Left heart obstruction was defined as a
itral valve area 2 cm2, an aortic valve area 1.5 cm2, or
peak LV outflow tract gradient 30 mm Hg.
NP measurements. Peripheral venous samples were ob-
ained in the seated position. Blood was collected into a tube
ontaining ethylenediaminetetraacetic acid and immediately
laced on ice. The sample was centrifuged at 1,800 g for 10
in at 4°C, and isolated plasma was stored at 80°C.
nalyses for BNP concentrations were performed within
months of sample acquisition. BNP was measured with a
hemiluminescence immunoassay kit on the i2000 Architect
latform (Fujirebio Diagnostics, Inc., Malvern, Pennsylvania).
ur laboratory and others use BNP levels 100 pg/ml to
efine a value suggestive of heart failure (11). In all cases where
NP was elevated (100 pg/ml), serum creatinine was mea-
ured to exclude renal dysfunction.
utcomes. As previously reported, adverse maternal car-
iac events were defined as any of the following: sustained
ymptomatic tachyarrhythmia or bradyarrhythmia requiring
reatment, stroke, cardiac arrest or cardiac death, pulmonary
dema (documented on chest radiograph or by crackles
eard over more than one-third of posterior lung fields), a
ecline in NYHA functional class (2 classes) compared
ith baseline, or need for urgent invasive cardiac procedures
uring pregnancy or within 6 months after delivery (7).
tatistical analyses. All data analyses were performed with
PSS (version 17.0, SPSS Inc., Chicago, Illinois). Contin-
ous variables are expressed as mean SD where indicated.
on-normal distributed variables, including BNP, were ex-
ressed as a median and interquartile range (IQR). The peak
NP was defined as the maximal level measured during the
tudy period. Differences in clinical and echocardiographic
ariables between patients with and without BNP levels100
g/ml or adverse maternal cardiac events were determined
ith chi-square, Fisher exact, or Student t tests as appro-
riate. Because BNP values were non-normally distributed,
ann-Whitney U tests were used to compare levels in
atients with and without adverse cardiac events. Similarly,
Friedman nonparametric test was used to compare BNP
evels at different time-points during pregnancy. A p value
0.05 (2-tailed) was considered significant.
esults
n total, 78 pregnant women were included in the study: 66
ith heart disease, and 12 healthy control subjects without
eart disease. Apart from heart disease, baseline character-
stics in women with and without heart disease were similar
mean age: 31  5 years vs. 33  5 years, p  0.31;
ulliparity: 42% vs. 42%, p  0.96; smoking during preg-
n
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October 5, 2010:1247–53 BNP and Pregnancyancy: 8% vs. 8%, p  0.58). Baseline characteristics and
chocardiographic characteristics in women with heart dis-
ase are outlined in Table 1. Of the 66 women with heart
isease, 74% (n 49) had congenital heart disease. None of
he women had more than mild systemic ventricular dys-
unction (ejection fraction 40% in all) at baseline, and none
ad cyanotic heart disease (oxygen saturation 90% in all).
Three women with heart disease and baseline measure-
ents had spontaneous abortions (aortic regurgitation after
epair of a sinus of Valsalva rupture [n  1], stenotic
aseline Maternal Characteristicsn Wom n With Heart DiseaseTable 1 Baseline M t rnal Characteristicsin Women With Heart Disease
Clinical characteristics
Maternal age at study (mean  SD) (yrs) 31 5
Median gestational age at enrollment (weeks) 13
Nulliparity 28 (42%)
Smoking in pregnancy 5 (8%)
Prior cardiac events (heart failure, arrhythmia, TIA, stroke) 11 (17%)
New York Heart Association functional class
I 54 (82%)
II 10 (15%)
II 2 (3%)
Cardiac diagnosis
Repaired tetralogy of Fallot or pulmonary valve disease 16 (24%)
Cardiomyopathy* 13 (20%)
Bicuspid aortic valve disease and/or aortic stenosis and/or aortic
regurgitation and/or LV outflow tract obstruction
10 (15%)
Intracardiac shunt lesions 7 (11%)
Repaired coarctation of aorta 5 (8%)
Mitral valve prolapse and/or mitral regurgitation 4 (6%)
Ebstein’s anomaly 3 (4%)
Rheumatic mitral stenosis 3 (4%)
Marfan syndrome 1 (2%)
Other 4 (6%)
Medications
Cardiac medications at first visit 10 (15%)
Receiving anticoagulants 6 (9%)
Echocardiographic parameters
Mean LVEF (%) 61 7
Mean left atrial volume (ml) 64 42
Left heart obstruction† 11 (17%)
Subaortic ventricular dilation (n  57)‡ 14 (25%)
Subaortic ventricular dysfunction§ 15 (23%)
Subpulmonic ventricular dilation 16 (24%)
Subpulmonic ventricular dysfunction¶ 8 (12%)
Pulmonary hypertension# 10 (15%)
Aortic or subaortic atrioventricular valve regurgitation moderate 9 (14%)
Pulmonic or subpulmonic atrioventricular valve regurgitation
moderate
12 (18%)
 66, unless otherwise indicated. Values given are n (%), unless otherwise indicated. *Cardio-
yopathy  dilated cardiomyopathy (n  3), hypertrophic cardiomyopathy (n  4), systolic
ysfunction post-anthracycline therapy (n  2), congenitally corrected transposition of the great
rteries (n  3), or previous peripartum cardiomyopathy with residual mild systolic dysfunction
n 1). †Left heart obstructionmitral valve area2 cm2 or aortic valve area1.5 cm2 or peak
eft ventricular (LV) outflow tract gradient30mmHg. ‡Subaortic ventricular dilation LV volume
104 ml, assessable in n  57 patients. §Subaortic ventricular dysfunction  left ventricular
jection fraction (LVEF) 55% (in 3 patients with systemic [subaortic] right ventricle, size and
unction assessed visually). Subpulmonic ventricular dilation  mild or greater dilation. ¶Subpul-
onic ventricular dysfunctionmild or more hypokinesis. #Pulmonary hypertension pulmonarys
rtery systolic pressure 40 mm Hg.
TIA  transient ischemic attack.icuspid aortic valve [n  1], Marfan syndrome with mitral
egurgitation [n  1]) and were not included in the
utcome analyses. One woman without heart disease was
ecruited but developed preeclampsia and was also not
ncluded in any analyses, due to the reported association
etween preeclampsia and elevations in natriuretic peptides
12,13).
NP during pregnancy in women with and without heart
isease. In all healthy control subjects, BNP levels were
ow and did not increase throughout pregnancy (peak
edian BNP: 35 pg/ml, IQR: 21 to 43 pg/ml). In women
ith heart disease, BNP levels (peak median BNP: 79
g/ml, IQR: 51 to 152, p 0.001) were higher than healthy
ontrol subjects (Fig. 1A). At all times during pregnancy
nd after delivery, BNP levels were significantly higher in
omen with heart disease compared with women without
eart disease (p  0.001). The range of BNP levels in
omen with heart disease was variable (range 15 to 1,425
g/ml) but was highest in women with subaortic ventricular
ysfunction (peak median BNP: 137 pg/ml, IQR: 55 to 261
g/ml, p 0.03) (Fig. 1B). Although subgroups were small,
o differences in BNP levels were identified among women
ith other specific cardiac diagnostic subgroups.
Over the course of pregnancy and after delivery, BNP
evels in a range suggestive of heart failure (BNP 100
g/ml) were found in 38% (24 of 63) of women with heart
isease; 10% (n  6) of women with heart disease had BNP
n this range in the first trimester, and this had increased to
6% (n  15) by the third trimester during peak hemody-
amic stress (Fig. 2). Five percent (3 of 66) of women in this
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Figure 1 BNP Levels During Pregnancy
(A) Median peak plasma B-type natriuretic peptide (BNP) levels were increased
in pregnant women with heart disease compared with healthy pregnant control
subjects. (B) Median plasma BNP levels were significantly greater in women
with heart disease who had subaortic ventricular dysfunction compared with
women with heart disease without subaortic ventricular dysfunction. Error bars
denote interquartile range. *p  0.05.tudy had a BNP level 500 pg/ml. None of the healthy
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BNP and Pregnancy October 5, 2010:1247–53ontrol subjects had BNP elevations in the range suggestive
f heart failure (BNP 100 pg/ml) at any time during
regnancy (Fig. 2). All women with BNP 100 had
ormal renal function as measured by the serum creati-
ine levels (mean creatinine 56  11 mol/l). Clinical
arameters associated with BNP levels 100 pg/ml are
hown in Table 2.
dverse maternal cardiac events and their association
ith BNP levels. Adverse maternal cardiac events occurred
n 13% (8 of 63) of women with heart disease (Table 3).
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Figure 2 Significant Elevations of BNP Levels
Early and Late in Pregnancy
Plasma B-type natriuretic peptide (BNP) levels in a range suggestive of heart
failure (BNP 100 pg/ml) were found in 10% of women with heart disease by
the first trimester and in 26% of women by the third trimester. None of the
healthy control subjects had a BNP 100 pg/ml at any time.
Relationship Between Baseline Maternal Characand Elevated BNP L vels in Pregn nt Women WTable 2 Relationship Betw e Baseline M tand Elevated BNP Levels in Pregna
Maternal age (mean  SD) (yrs)
Prior cardiac events (heart failure, TIA, stroke)
Baseline New York Heart Association functional class II
Cardiac medications
Left heart obstruction*
Subaortic ventricular dilation (n  57)†
Subaortic ventricular dysfunction‡
Subpulmonic ventricular dilation§
Subpulmonic ventricular dysfunction
Pulmonary hypertension¶
Aortic or subaortic atrioventricular valve regurgitation mo
Pulmonic or subpulmonic atrioventricular valve regurgitatio
*Left heart obstruction  mitral valve area 2 cm2 or aortic valve a
ventricular dilation  LV volume 104 ml, assessable in n  57 pa
systemic [subaortic] right ventricle, size and function assessed visually
ventricular dysfunction  mild or more hypokinesis. ¶Pulmonary hypertensio
BNP  B-type natriuretic peptide; TIA  transient ischemic attack.here was 1 maternal death at 17 weeks gestation in a
oman with hypertrophic cardiomyopathy. She had a fam-
ly history of sudden death, and a prophylactic internal
ardiac defibrillator was inserted before pregnancy. Early in
regnancy she had recurrent atrial arrhythmias and heart
ailure. She was clinically stable at the time her BNP level
BNP 1,425 pg/ml) was obtained. At 17 weeks gestation,
he had a witnessed cardiac arrest. Three patients developed
eart failure, 2 of whom had an associated deterioration in
entricular function after delivery. Three women developed
rrhythmias: 2 had supraventricular tachycardias, and 1 had
combination of atrial fibrillation and recurrent nonsus-
ained ventricular tachycardia. One woman with a mechan-
cal systemic atrioventricular valve replacement developed
alve thrombosis at 12 weeks gestation after being subthera-
eutically anticoagulated. All 8 women with adverse cardiac
vents had significantly elevated peak BNP levels (median
eak BNP 354, IQR 229 to 805 pg/ml). The increased
NP measurements predated or occurred at the time of
ecompensation in 88% (7 of 8) of women; increased BNP
evels predated the adverse cardiac event in 4 women, and
evels were drawn at the time of decompensation in 3
omen. In 1 woman (a 31-year-old woman with biopros-
hetic mitral valve replacement) the elevated BNP measure-
ent was obtained after the first episode of supraventricular
achyarrhythmia.
The univariate predictors of maternal cardiac events in
omen with heart disease are outlined in Table 3. Com-
ared with women with no maternal cardiac events, women
ith adverse cardiac events during pregnancy were more
ikely to have had a history of adverse cardiac events
ntedating pregnancy (p 0.003) and lower baseline LVEF
p  0.006) and were more likely to be taking cardiac
edications (p  0.003) or anticoagulants (p  0.002) at
aseline. Peak BNP levels were significantly higher in
ticseart Diseasel Characteristics
men With Heart Disease
BNP >100 pg/ml
(n  24)
BNP <100 pg/ml
(n  42) p Value
31 6 31 5 0.90
7 (29%) 4 (10%) 0.09
2 (8%) 0 0.14
10 (42%) 1 (3%) 0.001
5 (21%) 6 (14%) 0.74
7 (29%) 5 (12%) 0.10
9 (38%) 6 (14%) 0.045
8 (33%) 8 (19%) 0.26
5 (21%) 3 (7%) 0.24
4 (17%) 6 (14%) 1.00
5 (21%) 3 (7%) 0.24
derate 4 (17%) 8 (19%) 1.00
.5 cm2 or peak LV outflow tract gradient 30 mm Hg. †Subaortic
Subaortic ventricular dysfunction  LVEF 55% (in 3 patients with
pulmonic ventricular dilationmild or greater dilation. Subpulmonicterisi h Herna
nt Wo
derate
n mo
rea 1
tients. ‡
). §Subn  pulmonary artery systolic pressure 40 mm Hg.
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October 5, 2010:1247–53 BNP and Pregnancyomen with cardiac events during pregnancy (p  0.001).
peak BNP 100 pg/ml occurred in 100% (8 of 8) of
omen with adverse maternal cardiac events, compared
ith 19% (16 of 55) of women without events (p  0.001).
BNP 100 pg/ml had, on the basis of this cohort, a
egative predictive value of 100% and a sensitivity and
pecificity of identifying women with maternal cardiac event
uring pregnancy of 100% and 70%, respectively.
Adverse maternal cardiac events during pregnancy ac-
ording to the maternal cardiac risk score (Cardiac Disease
n Pregnancy risk score) were 2%, 30%, and 50% for women
ith 0 (n  41), 1 (n  20), and 1 (n  2) risk scores,
espectively. Because there were only 2 women with risk
cores 1, it was not possible to determine the incremental
alue of high BNP levels for this subgroup. However,
stimates of maternal adverse event rates in women with a
isk score of 0 or 1 differed when BNP levels were
ncorporated into risk estimates. In women with risk scores
f 0 (low risk for adverse cardiac events), the rates of adverse
aternal cardiac events during pregnancy were 0 in women
ith BNP levels 100 pg/ml and 8% in women with BNP
evels 100 pg/ml. In women with risk scores of 1 (inter-
ediate risk for adverse cardiac events), rates of adverse
ardiac events were 0 in women with BNP levels 100
g/ml and 60% in women with BNP 100 pg/ml (p 
.03). However, elevated BNP level (BNP100 pg/ml) did
ot predate the adverse cardiac event in all women, and
herefore the role of BNP in predicting adverse events could
ot be determined.
dverse fetal/neonatal and obstetric events in women
ith heart disease. Adverse fetal and/or neonatal events
ccurred in 9 pregnancies: 2 fetal deaths, 4 premature births
37 weeks gestation, 2 of which had associated respiratory
redictors of Adverse Maternal Cardiac Events in Women With HeaTable 3 Predictors of Adverse Maternal Cardiac Events in Wom
Adve
Maternal age, mean  SD (yrs)
Cardiac event before pregnancy
New York Heart Association functional class 2
Use of cardiac medications
Use of anticoagulants
Subaortic ventricular dysfunction*
Subaortic ventricular dilation (n  57)†
Left heart obstruction‡
Aortic or subaortic atrioventricular valve regurgitation moderate
Pulmonic or subpulmonic atrioventricular valve regurgitation moderate
Pulmonary arterial hypertension§
LVEF on initial echocardiogram (%)
BNP max (pg/ml), median (IQR)
Maximum BNP 100 pg/ml
Initial BNP 100 pg/ml
Subaortic ventricular dysfunction LVEF55% (in 3 patients with systemic [subaortic] right ventri
n 57 patients. ‡Left heart obstruction  mitral valve area 2 cm2 or aortic valve area 1.5 cm
ressure 40 mm Hg.
IQR  interquartile range; other abbreviations as in Table 1.istress), and 3 low birth-weight (2,500 g) births. Peak rNP levels were not associated with adverse fetal and/or
eonatal events (p  0.77). Pregnancy-induced hyperten-
ion (blood pressure increase of systolic30 mm Hg and/or
iastolic 15 mm Hg) was observed in 6 pregnancies.
here were no occurrences of after-delivery hemorrhage.
he BNP levels were similar (p  0.25) in women with or
ithout pregnancy-induced hypertension.
iscussion
his is the first study to examine BNP levels in pregnant
omen with heart disease. During pregnancy, many women
ith heart disease had increased BNP levels. Normal levels
f BNP during pregnancy in women with heart disease were
n important finding, predicting a low risk for adverse
aternal cardiac events. There is a subset of women with
levated BNP levels in the range typically found in patients
ith clinical heart failure who did not show clinical decom-
ensation during pregnancy; the significance of this finding
s presently unknown.
We found that, similar to findings of previous studies
12,14,15), despite the hemodynamic load of pregnancy,
ost healthy pregnant women have low and stable concen-
rations of BNP throughout pregnancy and after delivery.
his suggests that healthy women are, in general, able to
ompensate for the increased volume load that occurs
uring pregnancy (16). By comparison, women with heart
isease have higher natriuretic peptide levels throughout
regnancy compared with nonpregnant women, suggesting
erhaps an impaired adaptation to the hemodynamic load of
regnancy.
Elevations in natriuretic peptides have been shown to
ccur in patients with heart disease in other conditions that
seaseith Heart Disease
aternal Cardiac Events
(n  8)
No Adverse Maternal Cardiac Events
(n  55) p Value
31 7 31 5 0.86
5 (63%) 6 (11%) 0.003
1 (13%) 1 (2%) 0.11
5 (63%) 6 (11%) 0.003
4 (63%) 2 (4%) 0.002
4 (50%) 11 (20%) 0.08
3/6 (50%) 9/49 (18%) 0.11
2 (25%) 9 (16%) 0.62
1 (13%) 7 (13%) 1.0
2 (25%) 10 (18%) 0.64
3/6 (50%) 7/45 (16%) 0.08
54 4 62 7 0.005
54, (229–805) 73, (43–131) 0.001
8 (100%) 16 (19%) 0.001
4 (50%) 2 (4%) 0.002
and function assessed visually). †Subaortic ventricular dilation LV volume104ml, assessable
k LV outflow tract gradient 30 mm Hg. §Pulmonary hypertension  pulmonary artery systolicrt Dien W
rse M
3
cle, size
2 or peaesemble pregnancy. For instance, hemodynamic changes of
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BNP and Pregnancy October 5, 2010:1247–53regnancy have some similarities to the changes seen with
xercise. In nonpregnant patients with heart disease (con-
enital and acquired), higher BNP levels at rest are corre-
ated with latent ventricular impairment only evident during
xercise (17,18). In these patients, increased baseline resting
atriuretic peptide levels might reflect subclinical abnormal-
ties that become clinically manifest only with the stress of
xercise. In women with preeclampsia, natriuretic BNP
evels are increased compared with healthy pregnant women
13,14). This is paralleled by increased LV wall mass and
V chamber dimensions (12). Furthermore, crystalloid
nfusion in women with preeclampsia leads to further rises
n atrial natriuretic peptide levels (19,20), a change not
ound in healthy pregnant women, suggesting that women
ith preeclampsia do not adequately compensate in re-
ponse to volume challenges. A similar phenomenon might
e present in women with underlying heart conditions who
ave less hemodynamic reserve and less ability to accom-
odate to the hemodynamic changes of pregnancy.
BNP levels in the range suggestive of heart failure were
ound in 38% of women with heart disease during preg-
ancy, including many who did not have clinical evidence of
ardiac decompensation. Although not known, this abnor-
al response could be a marker of limited cardiac reserve
ith prognostic significance late after pregnancy. This
roup requires further study.
Clinically, women with ventricular dysfunction represent
group at high risk for cardiac complications during
regnancy. Not unexpectedly, BNP was highest during
regnancy in this group of women, in both those with and
ithout clinical events. Elevations in BNP during preg-
ancy suggest that volume overload and subsequent ventric-
lar dilation might explain, at least in part, the mechanism
esponsible for clinical deterioration. There are some data to
uggest that pregnancy adversely affects the natural course of
he disease in women with LV systolic function (21) and
ight have late effects on the function of the ventricles
22,23). Therefore, this group of women, specifically those
ith abnormally high BNP levels during pregnancy, should
ave continued surveillance after pregnancy.
Early identification of deterioration in status, before acute
vents, is particularly important in pregnant women with
eart disease, because acute conditions are often dangerous
or both the mother and the fetus, and treatment options
ight be constrained because of the pregnant state. Because
arly detection is important, studies have focused on risk
tratification with antenatal echocardiographic and clinical
ariables (7,8); however, no studies have examined the
tility of biomarkers or other measures with the ability to
ssess the adaptation of the heart to the hemodynamic load
f pregnancy. We found that serial BNP measurements
uring pregnancy incorporated into traditional antenatal
isk assessment were able to improve risk stratification in
ome cases. More importantly, BNP levels 100 pg/ml had
very high negative predictive value for adverse maternalardiac events. Therefore, BNP could be potentially usefulhen confusion exists regarding the clinical cardiac status in
regnant women with cardiac disease.
tudy limitations. This study investigated serial changes in
NP levels in women with various structural cardiac dis-
ases. Because of the relatively small number of women in
ach of the cardiac diagnostic subgroups, difference in
atriuretic peptide response to pregnancy between women
ith differing cardiac lesions could not be determined. We
id not assess women with arrhythmias and structurally
ormal hearts, a group of patients who commonly present in
regnancy. In previous work from our group, poor func-
ional class (NYHA functional class 2), cyanosis, and
mpaired ventricular function (LVEF 40%) were clinical
isk factors for predicting maternal cardiac events (7).
owever, we were unable to determine the independent
ole of BNP in predicting adverse maternal cardiac out-
omes during pregnancy. Perhaps, with a larger sample size,
ore frequent BNP measurement during pregnancy, or
ith the use of a range of BNP thresholds, the positive
redictive value of BNP to identify high-risk women could
e determined. Furthermore, although our laboratory and
thers use BNP levels 100 pg/ml to define a value
uggestive of heart failure, there is debate regarding the
ptimal BNP threshold to diagnose heart failure. With a
arger sample size, other BNP thresholds might prove to be
linically important in this cohort.
onclusions
NP levels are elevated in many women with heart disease
uring pregnancy. Normal levels of BNP during pregnancy
n women with heart disease are an important finding and
redict low risk for adverse maternal cardiac events. Con-
ersely, high levels can be associated with adverse maternal
ardiac events. There exists a subgroup of pregnant women
ith heart disease who have elevated levels of natriuretic
eptide levels during pregnancy but do not have clinical
vents. The significance of this finding requires further
tudy.
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